SG10201912338RA - Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) - Google Patents
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)Info
- Publication number
- SG10201912338RA SG10201912338RA SG10201912338RA SG10201912338RA SG10201912338RA SG 10201912338R A SG10201912338R A SG 10201912338RA SG 10201912338R A SG10201912338R A SG 10201912338RA SG 10201912338R A SG10201912338R A SG 10201912338RA SG 10201912338R A SG10201912338R A SG 10201912338RA
- Authority
- SG
- Singapore
- Prior art keywords
- fluoruracil
- leucovorin
- oxaliplatin
- gastric cancer
- combination therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416317P | 2016-11-02 | 2016-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912338RA true SG10201912338RA (en) | 2020-02-27 |
Family
ID=60569939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903615WA SG11201903615WA (en) | 2016-11-02 | 2017-11-01 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| SG10201912338RA SG10201912338RA (en) | 2016-11-02 | 2017-11-01 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903615WA SG11201903615WA (en) | 2016-11-02 | 2017-11-01 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11071726B2 (en) |
| EP (1) | EP3535026A1 (en) |
| JP (2) | JP2019533684A (en) |
| KR (1) | KR20190077441A (en) |
| CN (1) | CN110402163A (en) |
| AU (1) | AU2017354903B2 (en) |
| BR (1) | BR112019007844A2 (en) |
| CA (1) | CA3040395A1 (en) |
| EA (1) | EA201990979A1 (en) |
| IL (2) | IL266187A (en) |
| MA (1) | MA46709A (en) |
| MX (1) | MX2019004783A (en) |
| MY (1) | MY202377A (en) |
| PH (1) | PH12019500892A1 (en) |
| RU (1) | RU2761953C2 (en) |
| SG (2) | SG11201903615WA (en) |
| TW (1) | TWI791467B (en) |
| WO (1) | WO2018083470A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PT3337467T (en) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| WO2017034957A1 (en) | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| CN116763734A (en) | 2017-03-31 | 2023-09-19 | 富士胶片株式会社 | Method for producing liposome composition |
| JP7057434B2 (en) * | 2018-10-01 | 2022-04-19 | 富士フイルム株式会社 | Combination drug containing a liposome composition containing a drug and a platinum preparation |
| WO2020079692A1 (en) * | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| KR20210130765A (en) * | 2019-02-22 | 2021-11-01 | 노보큐어 게엠베하 | Gastric cancer treatment by combining XELOX, FOLFOX, or each of its components with TTFIELD |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (en) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | Novel camptothecin derivative |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (en) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (en) | 1996-01-31 | 1997-08-07 | Schering Ag | New selective taxanes, processes for their preparation and their pharmaceutical use |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| WO1998017256A1 (en) | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| EP1121102B1 (en) | 1998-09-16 | 2003-04-23 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| DE60123583T2 (en) | 2000-02-04 | 2007-08-09 | Lipoxen Technologies Ltd. | DEHYDRATISATION / REHYDRATISATION PROCESS FOR THE PREPARATION OF LIPOSOME |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| DK1286671T3 (en) | 2000-05-15 | 2006-07-17 | Celgene Corp | Compositions for the treatment of colorectal cancers containing thalidomide and irinotecan |
| DE60115044T2 (en) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Liposomal antineoplastic drugs and their uses |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| MXPA03008864A (en) | 2001-03-26 | 2004-12-06 | Johnson & Johnson | Liposome composition for improved intracellular delivery of a therapeutic agent. |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| AU2002328945A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| WO2003097805A2 (en) | 2002-05-15 | 2003-11-27 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| EP2431385A3 (en) | 2002-05-31 | 2012-07-04 | Morphotek, Inc. | Combination therapy with chlorotoxin |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| KR20170073698A (en) | 2003-05-30 | 2017-06-28 | 제넨테크, 인크. | Treatment with anti-VEGF antibodies |
| DK1746976T3 (en) | 2004-05-03 | 2017-04-10 | Merrimack Pharmaceuticals Inc | LIPOSOMES SUITABLE FOR PHARMACEUTICAL SUPPLY |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| MXPA06013874A (en) * | 2004-06-01 | 2007-04-25 | Terumo Corp | Irinotecan preparation. |
| JP2006248978A (en) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US20100189771A1 (en) | 2005-10-25 | 2010-07-29 | Lawrence Mayer | Fixed ratio drug combination treatments for solid tumors |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| CN101370497B (en) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | Combination product with PARP inhibitors and cell toxin and its uses |
| US20070219268A1 (en) | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| PT2716301T (en) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| WO2009097011A1 (en) | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| WO2009040426A1 (en) | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| WO2009064444A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN101888777A (en) | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
| JP2011515478A (en) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| KR20110008086A (en) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | Human serum albumin linkers and conjugates thereof |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| BRPI0921586A2 (en) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | human serum albumin articulators and conjugates thereof |
| NZ596365A (en) | 2009-05-01 | 2013-11-29 | Oncozyme Pharma Inc | Pentamidine combinations for treating cancer |
| KR20120089754A (en) | 2009-12-03 | 2012-08-13 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| RU2576609C2 (en) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Methods of treating pancreatic cancer |
| WO2012012454A1 (en) | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
| RU2598711C2 (en) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Anti-tumour antigen antibody and methods of application |
| RU2541100C2 (en) | 2010-09-03 | 2015-02-10 | Боард Оф Регентс Оф Зе Юниверсити Оф Небраска | Method and composition for treating cancer |
| CN107252417A (en) | 2010-12-06 | 2017-10-17 | 梅里麦克制药股份有限公司 | Dosage and the administration of myocardium toxicity are prevented in the treatment using the ERBB2 targeting immunoliposomes comprising anthracycline chemotherapy agent |
| JP5947807B2 (en) | 2010-12-14 | 2016-07-06 | テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ | Encapsulation of radionuclides in nanoparticle compositions |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| BR112013027021A2 (en) | 2011-04-19 | 2016-11-29 | Merrimack Pharmaceuticals Inc | monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
| AU2013249307B2 (en) | 2012-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| RU2668125C2 (en) | 2013-03-27 | 2018-09-26 | Тайхо Фармасьютикал Ко., Лтд. | Low-dose antitumor agent including irinotecan hydrochloride hydrate |
| JP2016529284A (en) | 2013-08-27 | 2016-09-23 | ノースイースタン ユニバーシティ | Nanoparticle drug delivery system and method for treating cancer and neurotrauma |
| WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| AU2015360761B2 (en) | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
| PT3337467T (en) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| WO2017034957A1 (en) | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| JP2019516693A (en) | 2016-05-18 | 2019-06-20 | イプセン バイオファーム リミティド | Nanoliposomal irinotecan for use in the treatment of small cell lung cancer |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
-
2017
- 2017-11-01 WO PCT/GB2017/053293 patent/WO2018083470A1/en unknown
- 2017-11-01 CN CN201780080584.XA patent/CN110402163A/en active Pending
- 2017-11-01 MX MX2019004783A patent/MX2019004783A/en unknown
- 2017-11-01 TW TW106137766A patent/TWI791467B/en active
- 2017-11-01 AU AU2017354903A patent/AU2017354903B2/en active Active
- 2017-11-01 KR KR1020197014970A patent/KR20190077441A/en not_active Application Discontinuation
- 2017-11-01 CA CA3040395A patent/CA3040395A1/en active Pending
- 2017-11-01 SG SG11201903615WA patent/SG11201903615WA/en unknown
- 2017-11-01 BR BR112019007844A patent/BR112019007844A2/en unknown
- 2017-11-01 EP EP17808557.7A patent/EP3535026A1/en not_active Ceased
- 2017-11-01 RU RU2019114952A patent/RU2761953C2/en active
- 2017-11-01 EA EA201990979A patent/EA201990979A1/en unknown
- 2017-11-01 SG SG10201912338RA patent/SG10201912338RA/en unknown
- 2017-11-01 MY MYPI2019002087A patent/MY202377A/en unknown
- 2017-11-01 MA MA046709A patent/MA46709A/en unknown
- 2017-11-01 JP JP2019522381A patent/JP2019533684A/en active Pending
- 2017-11-01 US US16/346,436 patent/US11071726B2/en active Active
-
2019
- 2019-04-23 IL IL266187A patent/IL266187A/en unknown
- 2019-04-24 PH PH12019500892A patent/PH12019500892A1/en unknown
-
2022
- 2022-03-24 IL IL291679A patent/IL291679A/en unknown
- 2022-09-15 JP JP2022146925A patent/JP2022171808A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2761953C2 (en) | 2021-12-14 |
| WO2018083470A1 (en) | 2018-05-11 |
| AU2017354903B2 (en) | 2023-04-13 |
| BR112019007844A2 (en) | 2019-07-16 |
| RU2019114952A3 (en) | 2021-03-03 |
| US20200030302A1 (en) | 2020-01-30 |
| MX2019004783A (en) | 2019-08-12 |
| TW201825097A (en) | 2018-07-16 |
| EP3535026A1 (en) | 2019-09-11 |
| RU2019114952A (en) | 2020-12-03 |
| AU2017354903A1 (en) | 2019-05-02 |
| IL291679A (en) | 2022-05-01 |
| JP2019533684A (en) | 2019-11-21 |
| US11071726B2 (en) | 2021-07-27 |
| SG11201903615WA (en) | 2019-05-30 |
| CA3040395A1 (en) | 2018-05-11 |
| MA46709A (en) | 2019-09-11 |
| MY202377A (en) | 2024-04-24 |
| PH12019500892A1 (en) | 2019-06-17 |
| TWI791467B (en) | 2023-02-11 |
| EA201990979A1 (en) | 2019-09-30 |
| KR20190077441A (en) | 2019-07-03 |
| CN110402163A (en) | 2019-11-01 |
| JP2022171808A (en) | 2022-11-11 |
| IL266187A (en) | 2019-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291679A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| HK1257250A1 (en) | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | |
| IL290695A (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| SI3640251T1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinoline derivatives useful in the treatment of cancer | |
| IL290149A (en) | Combination therapy for cancer treatment | |
| IL254006A0 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| EP3364870A4 (en) | Devices, systems, and methods for stimulation therapy | |
| EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
| IL255060A0 (en) | Combination therapy for treating cancer | |
| ZA201905222B (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
| EP3407978A4 (en) | Combination therapy for treating cancer | |
| GB201516504D0 (en) | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer | |
| HUE055433T2 (en) | Combined preparations for the treatment of cancer | |
| IL262656A (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| EP3639829A4 (en) | Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug | |
| IL262143A (en) | Improvements in cancer treatment | |
| EP3295949A4 (en) | Topical drug for treating breast cancer and preparation method thereof | |
| EP4031655A4 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| EP3283529A4 (en) | Agents, systems and methods for treating cancer | |
| IL249860A0 (en) | Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer | |
| PL3010508T3 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
| EP3684401A4 (en) | Therapeutic combination and method for treating cancer | |
| GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment | |
| GB201720089D0 (en) | Means and methods for treating cancer |